AR073425A1 - Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina - Google Patents

Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina

Info

Publication number
AR073425A1
AR073425A1 ARP090104547A ARP090104547A AR073425A1 AR 073425 A1 AR073425 A1 AR 073425A1 AR P090104547 A ARP090104547 A AR P090104547A AR P090104547 A ARP090104547 A AR P090104547A AR 073425 A1 AR073425 A1 AR 073425A1
Authority
AR
Argentina
Prior art keywords
antibody
citarabine
antitumoral
specifically recognize
containing antibodies
Prior art date
Application number
ARP090104547A
Other languages
English (en)
Inventor
Pascale Lejeune
Patricia Vrignaud
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40627502&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR073425(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR073425A1 publication Critical patent/AR073425A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

Reivindicacion 1: Una combinacion farmacéutica que comprende un anticuerpo que reconoce específicamente la CD38 y al menos citarabina, en la que dicho anticuerpo es capaz de destruir una célula CD38+ por apoptosis, citotoxicidad celular dependiente de anticuerpos (ADCC) y citotoxicidad dependiente de complemento (CDC). Reivindicacion 2: La combinacion segun la reivindicacion 1, en la que dicho anticuerpo es un anticuerpo humanizado. Reivindicacion 3: La combinacion segun la reivindicacion 2, en la que dicho anticuerpo comprende una o más regiones determinantes de la complementariedad que tienen una secuencia de aminoácidos elegida entre el grupo que consiste en las SEQ ID NOS 1, 2, 3 ,4, 5, 6, 7, 8. 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21. 22, 23, 24. 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 y 36. Reivindicacion 6: Uso de un anticuerpo que reconoce específicamente la CD38 para la preparacion de una combinacion farmacéutica segun la reivindicacion 1 para la elaboracion de un medicamento para el tratamiento del cáncer.
ARP090104547A 2008-11-28 2009-11-25 Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina AR073425A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08291118A EP2191842A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine

Publications (1)

Publication Number Publication Date
AR073425A1 true AR073425A1 (es) 2010-11-03

Family

ID=40627502

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104547A AR073425A1 (es) 2008-11-28 2009-11-25 Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina

Country Status (38)

Country Link
US (1) US20120093806A1 (es)
EP (2) EP2191842A1 (es)
JP (2) JP2012510463A (es)
KR (1) KR101715958B1 (es)
CN (2) CN102264386A (es)
AR (1) AR073425A1 (es)
AU (1) AU2009321251B2 (es)
BR (1) BRPI0921858B1 (es)
CA (1) CA2745005C (es)
CL (1) CL2011001232A1 (es)
CO (1) CO6440556A2 (es)
CR (1) CR20110282A (es)
DK (1) DK2370096T5 (es)
EA (1) EA027070B1 (es)
EC (1) ECSP11011071A (es)
ES (1) ES2638926T3 (es)
HN (1) HN2011001423A (es)
HR (1) HRP20171301T1 (es)
HU (1) HUE035910T2 (es)
IL (2) IL213118A (es)
LT (1) LT2370096T (es)
MA (1) MA32899B1 (es)
MX (1) MX344973B (es)
NI (1) NI201100107A (es)
NZ (1) NZ593085A (es)
PA (1) PA8849901A1 (es)
PE (1) PE20120205A1 (es)
PL (1) PL2370096T3 (es)
PT (1) PT2370096T (es)
RS (1) RS56248B1 (es)
SG (1) SG171821A1 (es)
SI (1) SI2370096T1 (es)
TN (1) TN2011000242A1 (es)
TW (1) TWI436770B (es)
UA (1) UA104160C2 (es)
UY (1) UY32266A (es)
WO (1) WO2010061359A1 (es)
ZA (1) ZA201104064B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
CN103118706B (zh) 2010-09-27 2016-05-18 莫佛塞斯公司 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
MX368288B (es) 2012-09-25 2019-09-27 Morphosys Ag Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple.
SG10201707464SA (en) 2013-03-13 2017-10-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
TN2016000142A1 (en) * 2013-10-31 2017-10-06 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers.
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
CR20170086A (es) 2014-09-09 2017-05-22 Janssen Biotech Inc Terapias de combinación con anticuerpos anti-cd38
CA2969717A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
CN108136218B (zh) 2015-05-20 2022-12-13 詹森生物科技公司 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
JP6816038B2 (ja) 2015-06-22 2021-01-20 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体及びサバイビン阻害剤による血液悪性疾患の併用療法
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CA2998611A1 (en) * 2015-09-14 2017-03-23 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating rhoh
MA53356B1 (fr) 2015-11-03 2022-05-31 Janssen Biotech Inc Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CA3079242A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
EP3938394A1 (en) 2019-03-15 2022-01-19 MorphoSys AG Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
WO2021113739A1 (en) 2019-12-05 2021-06-10 Thomas Ballet Formulations of anti-cd38 antibodies for subcutaneous administration
MX2023008187A (es) 2021-01-14 2023-07-18 Morphosys Ag Anticuerpos anti-cd38 y sus usos.
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
CN113278075B (zh) * 2021-06-18 2021-12-14 芜湖森爱驰生物科技有限公司 一种炎症检测试剂盒
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE387495T1 (de) 1996-12-03 2008-03-15 Amgen Fremont Inc Vollkommen humane antikörper die egfr binden
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP2003524587A (ja) * 1998-06-05 2003-08-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
SI2567976T1 (sl) * 2005-03-23 2017-11-30 Genmab A/S Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
JP5476122B2 (ja) * 2006-09-26 2014-04-23 ゲンマブ エー／エス Ｃｄ３８発現腫瘍の併用処置法
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2009206506B2 (en) * 2008-01-23 2013-01-10 Xencor, Inc. Optimized CD40 antibodies and methods of using the same
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine

Also Published As

Publication number Publication date
BRPI0921858A2 (pt) 2018-10-09
PL2370096T3 (pl) 2017-10-31
TN2011000242A1 (en) 2012-12-17
LT2370096T (lt) 2017-09-25
US20120093806A1 (en) 2012-04-19
RS56248B1 (sr) 2017-11-30
SG171821A1 (en) 2011-07-28
KR101715958B1 (ko) 2017-03-14
IL213118A0 (en) 2011-07-31
NI201100107A (es) 2011-09-26
CA2745005A1 (en) 2010-06-03
PT2370096T (pt) 2017-09-08
AU2009321251B2 (en) 2016-06-09
HUE035910T2 (en) 2018-05-28
PA8849901A1 (es) 2010-07-27
EA027070B1 (ru) 2017-06-30
BRPI0921858B1 (pt) 2022-11-16
UA104160C2 (uk) 2014-01-10
MA32899B1 (fr) 2011-12-01
IL213115A0 (en) 2011-07-31
HRP20171301T1 (hr) 2017-10-20
EP2370096A1 (en) 2011-10-05
DK2370096T5 (en) 2017-09-18
DK2370096T3 (en) 2017-07-17
SI2370096T1 (sl) 2017-10-30
IL213118A (en) 2017-08-31
ZA201104064B (en) 2012-09-26
CN107096022A (zh) 2017-08-29
HN2011001423A (es) 2014-01-13
UY32266A (es) 2010-06-30
JP2015205893A (ja) 2015-11-19
TW201023863A (en) 2010-07-01
JP2012510463A (ja) 2012-05-10
EP2191842A1 (en) 2010-06-02
CN102264386A (zh) 2011-11-30
EP2370096B1 (en) 2017-05-31
EA201100868A1 (ru) 2011-10-31
JP6072854B2 (ja) 2017-02-01
CL2011001232A1 (es) 2012-02-10
CR20110282A (es) 2011-09-20
MX2011005666A (es) 2011-09-30
AU2009321251A1 (en) 2010-06-03
CA2745005C (en) 2020-08-11
KR20110096551A (ko) 2011-08-30
NZ593085A (en) 2012-12-21
TWI436770B (zh) 2014-05-11
CO6440556A2 (es) 2012-05-15
PE20120205A1 (es) 2012-03-03
MX344973B (es) 2017-01-12
WO2010061359A1 (en) 2010-06-03
ES2638926T3 (es) 2017-10-24
ECSP11011071A (es) 2011-07-29
IL213115A (en) 2017-08-31

Similar Documents

Publication Publication Date Title
AR073425A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina
AR074219A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
AR074221A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamida
AR084196A1 (es) Composiciones antitumorales que contienen anticuerpos que reconocen especificamente cd38
CL2012002012A1 (es) Anticuerpo anti-cd38 o fragmento de este, capaz de destruir una célula cd38+ por apoptosis, citotoxicidad celular adcc y citotoxicidad cdc; anticuerpo humanizado; polinucleótido, vector y célula huésped que lo codifican; conjugado del anticuerpo con un compuesto citotóxico; composición farmacéutica con dichos anticuerpos; uso de los anticuerpos para tratar cáncer o enfermedad autoinmune; método para diagnosticar cáncer.
AR074220A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y vincristina y uso
AR122771A2 (es) Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped
AR071891A1 (es) Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
AR124676A2 (es) Formulación farmacéutica que comprende una droga biofarmacéutica
AR106752A1 (es) Proteínas de unión a pd1 / ctla4
PE20131209A1 (es) Anticuerpos anti-fap
EA201290370A1 (ru) Антитела против flt3 и способы их применения
AR095432A1 (es) Proteínas de unión a antígeno
CO6190538A2 (es) Agente para prevenir/tratar el cancer
RU2014138039A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
PE20061324A1 (es) Anticuerpos anti-il-6, composiciones, metodos y usos
CO6230999A2 (es) Anticuerpo anti-esclerostina
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
AR071733A1 (es) Terapia combinada de un anticuerpo anti-cd20 tipo ii con un inhibidor de proteasoma
PE20121563A1 (es) Anticuerpos que se unen especificamente al receptor epha2
PE20141151A1 (es) Proteinas de union al antigeno cd27l
RU2014147741A (ru) Модифицированные области антител и их применение

Legal Events

Date Code Title Description
FC Refusal